Last Updated: 19/06/2024
Development of Plasmodium vivax vaccine effective both for protection and transmission blocking
Objectives
*Original title and abstract were machine translated from Japanese.
This study proposes a general-purpose purely domestic vaccine platform for emerging and re-emerging infectious diseases that may cause outbreaks.
The study will develop a vivax vaccine based on the unique vaccine platform (LC16m8delta / AAV) consisting of the vaccinia virus vaccine strain LC16m8delta and the adeno-associated virus AAV. An LC16m8delta / AAV vaccine has been prepared into which a target antigen gene was introduced to prevent infection and prevent transmission of Plasmodium vivax. Animal immunity-Infection challenge experiment (mouse model) and artificial membrane mosquito blood sucking experiment using infected person’s blood were conducted, and numerical targets of infection protection effect> 90% and transmission prevention effect> 90% were set as milestones for 3 years.
Apr 2022 — Mar 2025
$146,578
Related Resources
